Clinical Efficacy and Safety of Evolocumab in High-Risk Patients With Low LDL or on Maximal-Potency Statin (FOURIER Secondary Analysis)

A natural objection to adding a PCSK9 inhibitor is that patients whose LDL is already low, or who are already on a maximal-strength statin, have little left to gain. This secondary analysis of the FOURIER trial tested that objection — and rejected it.

Evolocumab reduced cardiovascular events to a similar degree whether patients started with LDL below 70 mg/dL or above it, and whether they were on a maximal-potency statin or a lesser one. The benefit did not depend on having “room” by conventional standards; pushing LDL still lower helped regardless of the starting point, without new safety concerns.

This reinforces the central FOURIER message and the broader CTT principle: the benefit comes from the absolute LDL reduction achieved, not from where you began. It argues against withholding further lowering simply because a patient’s LDL already looks acceptable.

We rate the evidence strong. As a pre-specified secondary analysis of a major randomized trial it is high-quality, supporting aggressive LDL lowering even in patients who appear well-treated — with the modest caveat that subgroup analyses are best read as confirmatory rather than independently definitive.